Report cover image

Global Rivaroxaban Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Feb 11, 2025
Length 177 Pages
SKU # APRC19857211

Description

Summary

Rivaroxaban is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceutica. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects last approximately 8–12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.

According to APO Research, The global Rivaroxaban market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Rivaroxaban is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Rivaroxaban is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Rivaroxaban is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Rivaroxaban is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Rivaroxaban include Bayer and J&J etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Rivaroxaban, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Rivaroxaban, also provides the sales of main regions and countries. Of the upcoming market potential for Rivaroxaban, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Rivaroxaban sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Rivaroxaban market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Rivaroxaban sales, projected growth trends, production technology, application and end-user industry.


Rivaroxaban Segment by Company

Bayer
J&J

Rivaroxaban Segment by Type

2.5 mg
10 mg
15 mg
20 mg

Rivaroxaban Segment by Application

Acute Coronary Syndrome (ACS)
Venous Thromboembolism (VTE)

Rivaroxaban Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rivaroxaban market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Rivaroxaban and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rivaroxaban.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Rivaroxaban market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Rivaroxaban manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Rivaroxaban in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Rivaroxaban in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

177 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Rivaroxaban Market Size, 2020 VS 2024 VS 2031
1.3 Global Rivaroxaban Market Size Estimates and Forecasts (2020-2031)
1.4 Global Rivaroxaban Sales Estimates and Forecasts (2020-2031)
1.5 Global Rivaroxaban Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Rivaroxaban Market Dynamics
2.1 Rivaroxaban Industry Trends
2.2 Rivaroxaban Industry Drivers
2.3 Rivaroxaban Industry Opportunities and Challenges
2.4 Rivaroxaban Industry Restraints
3 Rivaroxaban Market by Manufacturers
3.1 Global Rivaroxaban Revenue by Manufacturers (2020-2025)
3.2 Global Rivaroxaban Sales by Manufacturers (2020-2025)
3.3 Global Rivaroxaban Average Sales Price by Manufacturers (2020-2025)
3.4 Global Rivaroxaban Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Rivaroxaban Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Rivaroxaban Manufacturers, Product Type & Application
3.7 Global Rivaroxaban Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Rivaroxaban Market CR5 and HHI
3.8.2 Global Top 5 and 10 Rivaroxaban Players Market Share by Revenue in 2024
3.8.3 2024 Rivaroxaban Tier 1, Tier 2, and Tier 3
4 Rivaroxaban Market by Type
4.1 Rivaroxaban Type Introduction
4.1.1 2.5 mg
4.1.2 10 mg
4.1.3 15 mg
4.1.4 20 mg
4.2 Global Rivaroxaban Sales by Type
4.2.1 Global Rivaroxaban Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Rivaroxaban Sales by Type (2020-2031)
4.2.3 Global Rivaroxaban Sales Market Share by Type (2020-2031)
4.3 Global Rivaroxaban Revenue by Type
4.3.1 Global Rivaroxaban Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Rivaroxaban Revenue by Type (2020-2031)
4.3.3 Global Rivaroxaban Revenue Market Share by Type (2020-2031)
5 Rivaroxaban Market by Application
5.1 Rivaroxaban Application Introduction
5.1.1 Acute Coronary Syndrome (ACS)
5.1.2 Venous Thromboembolism (VTE)
5.2 Global Rivaroxaban Sales by Application
5.2.1 Global Rivaroxaban Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Rivaroxaban Sales by Application (2020-2031)
5.2.3 Global Rivaroxaban Sales Market Share by Application (2020-2031)
5.3 Global Rivaroxaban Revenue by Application
5.3.1 Global Rivaroxaban Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Rivaroxaban Revenue by Application (2020-2031)
5.3.3 Global Rivaroxaban Revenue Market Share by Application (2020-2031)
6 Global Rivaroxaban Sales by Region
6.1 Global Rivaroxaban Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Rivaroxaban Sales by Region (2020-2031)
6.2.1 Global Rivaroxaban Sales by Region (2020-2025)
6.2.2 Global Rivaroxaban Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Rivaroxaban Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Rivaroxaban Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Rivaroxaban Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Rivaroxaban Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Rivaroxaban Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Rivaroxaban Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Rivaroxaban Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Rivaroxaban Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Rivaroxaban Revenue by Region
7.1 Global Rivaroxaban Revenue by Region
7.1.1 Global Rivaroxaban Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Rivaroxaban Revenue by Region (2020-2025)
7.1.3 Global Rivaroxaban Revenue by Region (2026-2031)
7.1.4 Global Rivaroxaban Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Rivaroxaban Revenue (2020-2031)
7.2.2 North America Rivaroxaban Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Rivaroxaban Revenue (2020-2031)
7.3.2 Europe Rivaroxaban Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Rivaroxaban Revenue (2020-2031)
7.4.2 Asia-Pacific Rivaroxaban Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Rivaroxaban Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Rivaroxaban Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Bayer
8.1.1 Bayer Comapny Information
8.1.2 Bayer Business Overview
8.1.3 Bayer Rivaroxaban Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Bayer Rivaroxaban Product Portfolio
8.1.5 Bayer Recent Developments
8.2 J&J
8.2.1 J&J Comapny Information
8.2.2 J&J Business Overview
8.2.3 J&J Rivaroxaban Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 J&J Rivaroxaban Product Portfolio
8.2.5 J&J Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Rivaroxaban Value Chain Analysis
9.1.1 Rivaroxaban Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Rivaroxaban Production Mode & Process
9.2 Rivaroxaban Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Rivaroxaban Distributors
9.2.3 Rivaroxaban Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.